Sotorasib plus carboplatin and pemetrexed in KRAS G12C advanced NSCLC: Updated analysis from the international CodeBreaK 101 trial

被引：0
|
作者：
Li, Bob T.
Clarke, Jeffrey Melson
Felip, Enriqueta
Ruffinelli, Jose Carlos
Garrido, Pilar
Zugazagoitia, Jon
Goldberg, Sarah B.
Ramalingam, Suresh S.
Victoria, Ivan
Puri, Sonam
Gandara, David R.
Kormany, William
Edmonds, Sophie
Palmer, Kerry
Gupta, Ravi G.
Govindan, Ramaswamy
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY USA
[2] Duke Univ, Durham, NC USA
[3] Vall dHebron Univ Hosp, Barcelona, Spain
[4] Inst Catala Oncol Hosp, Barcelona, Spain
[5] Ramon y Cajal Univ Hosp, Madrid, Spain
[6] Hosp Univ 12 Octubre, Madrid, Spain
[7] Yale Sch Med, New Haven, CT USA
[8] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[9] Hosp Clin Barcelona, Barcelona, Spain
[10] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[11] Univ Calif Davis, Ctr Comprehens Canc, Sacramento, CA 95817 USA
[12] Amgen Inc, Thousand Oaks, CA USA
[13] Amen Ltd, Cambridge, England
[14] Amgen Ltd, Cambridge, England
[15] Washington Univ, Sch Med, St Louis, MO USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8512
引用
收藏
页数：1
相关论文
共 50 条
  • [1] CodeBreaK 101: Safety and Efficacy of Sotorasib with Carboplatin and Pemetrexed in KRAS G12C-Mutated Advanced NSCLC
    Clarke, J. M.
    Felip, E.
    Li, B. T.
    Ruffinelli, J. C.
    Garrido, P.
    Zugazagoitia, J.
    Goldberg, S. B.
    Ramalingam, S. S.
    Victoria, I.
    Puri, S.
    Gandara, D. R.
    Varrieur, T.
    Edmonds, S.
    Palmer, K.
    Snyder, W.
    Govindan, R.
    Rybkin, I.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S118 - S119
  • [2] Registrational phase 2 trial of sotorasib in KRAS p. G12C mutant NSCLC: first disclosure of the CodeBreaK 100 primary analysis
    Schuler, M.
    Li, B. T.
    Skoulidis, F.
    Falchook, G.
    Sacher, A.
    Velcheti, V.
    Dy, G. K.
    Price, T.
    Borghaei, H.
    Kato, T.
    Takahashi, T.
    Spira, A.
    Ramalingam, S.
    Besse, B.
    Barlesi, F.
    Tran, Q.
    Henary, H.
    Ngarmchamnanrith, G.
    Govindan, R.
    Wolf, J.
    PNEUMOLOGIE, 2021, 75 : S38 - S38
  • [3] Patient-reported outcomes in CodeBreaK 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation
    Waterhouse, David M.
    Rothschild, Sacha
    Dooms, Christophe
    Mennecier, Bertrand
    Bozorgmehr, Farastuk
    Majem, Margarita
    Heuvel, Michel H. van den
    Linardou, Helena
    Cho, Byoung Chul
    Roberts-Thomson, Rachel
    Tanaka, Kentaro
    Blais, Normand
    Schvartsman, Gustavo
    Hansen, Karin Holmskov
    Chmielewska, Izabela
    Forster, Martin D.
    Giannopoulou, Christina
    Stollenwerk, Bjorn
    Obiozor, Cynthia C.
    Wang, Yang
    Novello, Silvia
    LUNG CANCER, 2024, 196
  • [4] CodeBreaK 100/101: First Report of Safety/Efficacy of Sotorasib in Combination with Pembrolizumab or Atezolizumab in Advanced KRAS p.G12C NSCLC
    Li, B. T.
    Falchook, G. S.
    Durm, G. A.
    Burns, T. F.
    Skoulidis, F.
    Ramalingam, S. S.
    Spira, A.
    Bestvina, C. M.
    Goldberg, S. B.
    Veluswamy, R.
    Iams, W. T.
    Chiappori, A. A.
    Lemech, C. R.
    Meloni, A. R.
    Ebiana, V.
    Dai, T.
    Gauto, D. M.
    Varrieur, T. L.
    Snyder, W. J.
    Govindan, R.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S10 - S11
  • [5] Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C
    Fakih, Marwan G.
    Salvatore, Lisa
    Esaki, Taito
    Modest, Dominik P.
    Lopez-Bravo, David P.
    Taieb, Julien
    Karamouzis, Michalis V.
    Ruiz-Garcia, Erika
    Kim, Tae-Won
    Kuboki, Yasutoshi
    Meriggi, Fausto
    Cunningham, David
    Yeh, Kun-Huei
    Chan, Emily
    Chao, Joseph
    Saportas, Yaneth
    Tran, Qui
    Cremolini, Chiara
    Pietrantonio, Filippo
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 389 (23): : 2125 - 2139
  • [6] Trial in Progress: A Phase 1b Study of Sotorasib, a KRAS (G12C) Inhibitor, in Combination with other Anticancer Therapies in Patients with Advanced Solid Tumors Harboring KRAS p.G12C Mutation (CodeBreaK101)
    Fakih, M.
    Durm, G.
    Govindan, R.
    Falchook, G.
    Soman, N.
    Henary, H.
    Hong, D. S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S28 - S28
  • [7] Use of sotorasib in KRAS p. G12C mutated NSCLC: a case report
    Barot, Hasti
    Evans, Joanne
    Mohammed, Waleed
    Power, Danielle
    LUNG CANCER, 2022, 165 : S77 - S77
  • [8] Sotorasib long-term clinical outcomes in pretreated KRAS G12C-mutated advanced NSCLC: Pooled analysis from the CodeBreaK clinical trials
    Skoulidis, F.
    Li, B. T.
    Hochmair, M. J.
    Govindan, R.
    Vincent, M.
    Van der Wekken, A. J.
    Reguart Aransay, N.
    O'Byrne, K. J.
    Girard, N.
    Griesinger, F.
    Nishio, M.
    Hafliger, S.
    Lindsay, C.
    Reinmuth, N.
    Paulus, A.
    Papakotoulas, P.
    Obiozor, C.
    Nduka, C.
    Wang, Y.
    De Langen, A. J.
    ANNALS OF ONCOLOGY, 2024, 35 : S830 - S831
  • [9] Registrational Phase 2 Trial of Sotorasib in KRAS p.G12C Mutant NSCLC: First Disclosure of the Codebreak 100 Primary Analysis
    Li, B.
    Skoulidis, F.
    Falchook, G.
    Sacher, A.
    Velcheti, V.
    Dy, G.
    Price, T.
    Borghaei, H.
    Schuler, M.
    Kato, T.
    Takahashi, T.
    Spira, A.
    Ramalingam, S.
    Besse, B.
    Barlesi, F.
    Tran, Q.
    Henary, H.
    Ngarmchamnanrith, G.
    Govindan, R.
    Wolf, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S61 - S61
  • [10] Comment on "Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRAS(G12C)-Mutated NSCLC Treated With Sotorasib"
    Jiang, Yanfang
    Zhang, Lei
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (09) : e43 - e43
12345